The Effects of Resveratrol on Sirtuins and Apoptosis Biomarkers

Coronary Artery Disease Clinical Trial

— RE-AGES  

Official title:

The Effects of Resveratrol on Inhibitors of Apoptosis Proteins, on Soluble Receptors of Advanced Glycation End Products and on Sirtuins-1 and -3 in Postmenopausal Women With Coronary Artery Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05808387
• Other study ID #: 61901722.6.0000.0068
• Status: Recruiting
• Phase: N/A
• Start date: March 6, 2023
• Est. completion date: June 5, 2026

Study information

• Verified date: March 2023
• Source: InCor Heart Institute
• Contact: Antonio P Mansur, PhD
• Phone: 551126615448
• Email: apmansur[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cardiovascular diseases (CVD) and neoplasms are the main causes of death in Brazilian women. Coronary artery disease (CAD) and stroke were responsible for approximately 54% of deaths from CVD in this population. In Brazil, cancers were the second cause of death and in 2017 were responsible for 58% of deaths in women. CVD and cancer share some risk factors, and control of these factors is associated with a significant reduction in cancer incidence. These two causes of death, although apparently disparate, share similar lifestyles and health risk factors, suggesting some common pathways and basic molecular networks. In women, the presence of estrogen has protective effects against atherosclerosis and, with the decline in hormone production at menopause, the incidence and prevalence of CAD increase substantially. Although the estrogen pathway is supposed to have a central effect on this increased risk, it is still debated whether other non-estrogenic mechanisms are related, since hormone replacement alone does not reduce cardiovascular events. Sirtuins and soluble advanced glycation product receptors (sRAGE) are associated with increased vascular protection, while the role of apoptosis inhibiting proteins, a pathway linked to increased cancer incidence, is still unclear in the context of atherosclerosis. Resveratrol is a key activator of sirtuins and potentially modulates these metabolic pathways, reducing cardiovascular risk. This randomized, double-blind, parallel, placebo-controlled clinical trial will be carried out in 80 postmenopausal women with CAD to analyze the effect of treatment with resveratrol on serum concentration and gene expression of sirtuins-1 -3, in the serum sRAGE concentration and in the gene expression of apoptosis inhibitory proteins.

Description:

The objective of the study is to evaluate the influence of sirtuins stimulation by resveratrol on inhibitors of apoptosis proteins gene expression of circulation angiogenic cells of postmenopausal women with stable coronary artery disease.

A randomized, double-blind, parallel, placebo-controlled clinical trial in postmenopausal women with CAD submitted to 90 days of daily resveratrol supplementation days of daily supplementation with 1000 mg of resveratrol. Eighty women aged ≥55 years, with overweight or obesity grade 1 (BMI between 25 and 35 kg/m2) will be selected. The participants will be randomized into two groups, control (CON) and resveratrol (RES). After the screening, the participants will undergo the first clinical and laboratory evaluation including lipid and glucose metabolism, inflammatory biomarkers, serum concentrations and gene expression of sirtuin-1 and sirtuin-3 and soluble receptor of advanced glycation end products, and the gene expression of inhibitors of apoptosis proteins.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: June 5, 2026
• Est. primary completion date: June 5, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Postmenopausal women;

• Diagnosed coronary artery disease;

• Stable coronary disease;

Exclusion Criteria:

• hypo or hyperthyroidism,

• rheumatic disease,

• use of alcohol,

• hepatic failure,

• renal failure

• hormone replacement therapy

• use of insulin

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Endothelial Dysfunction
• Menopause
• Myocardial Ischemia

Intervention

Dietary Supplement:
• Resveratrol
Trans-resveratrol, 1000 mg daily for 90 days
• Placebo
Starch, 1000 mg daily for 90 days

Locations

Country	Name	City	State
Brazil	INCOR- Heart Institute	Sao Paulo	São Paulo

Sponsors (1)

Lead Sponsor	Collaborator
InCor Heart Institute

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sirtuin-1 and sirtuin-3	Serum concentrations and gene expression	90 days
Primary	Inhibitors of apoptosis proteins	Gene expression of Bcl-2, XIAP, c-IAP1, and survivin	90 days
Primary	sRAGE	Serum concentrations and gene expression	90 days
Secondary	Inflammation	Serum concentrations of proinflammatory cytokines	90 days
Secondary	Cardiometabolic risk factors	Lipid and glucometabolic profiles	90 days
Secondary	Anthropometric measures	BMI, skinfold thickness, and body composition	90 days